AstraZeneca wins priority review schedule for leukemia drug; Penn gene therapy upstart grabs $9.29M with Frazier’s help – Endpoints News
Endpoints News |
AstraZeneca wins priority review schedule for leukemia drug; Penn gene therapy upstart grabs $9.29M with Frazier's help
Endpoints News With major help from Frazier Healthcare Partners, a stealthy gene therapy company from the University of Pennsylvania has secured $9.29 million in investment. Gene therapy pioneer James Wilson co-registered the company in 2016, the Philadelphia … |
